Stifel Maintains Buy on Janux Therapeutics, Lowers Price Target to $38
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
Stifel analyst Bradley Canino maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers the price target from $46 to $38.
Stifel analyst Bradley Canino maintains Janux Therapeutics (NASDAQ:JANX) with a Buy and lowers the price target from $46 to $38.